Literature DB >> 22203602

Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication.

Akiko Kusano-Kitazume1, Naoya Sakamoto, Yukiko Okuno, Yuko Sekine-Osajima, Mina Nakagawa, Sei Kakinuma, Kei Kiyohashi, Sayuri Nitta, Miyako Murakawa, Seishin Azuma, Yuki Nishimura-Sakurai, Masatoshi Hagiwara, Mamoru Watanabe.   

Abstract

To identify novel compounds that possess antiviral activity against hepatitis C virus (HCV), we screened a library of small molecules with various amounts of structural diversity using an HCV replicon-expressing cell line and performed additional validations using the HCV-JFH1 infectious-virus cell culture. Of 4,004 chemical compounds, we identified 4 novel compounds that suppressed HCV replication with 50% effective concentrations of ranging from 0.36 to 4.81 μM. N'-(Morpholine-4-carbonyloxy)-2-(naphthalen-1-yl) acetimidamide (MCNA) was the most potent and also produced a small synergistic effect when used in combination with alpha interferon. Structure-activity relationship (SAR) analyses revealed 4 derivative compounds with antiviral activity. Further SAR analyses revealed that the N-(morpholine-4-carbonyloxy) amidine moiety was a key structural element for antiviral activity. Treatment of cells with MCNA activated nuclear factor κB and downstream gene expression. In conclusion, N-(morpholine-4-carbonyloxy) amidine and other related morpholine compounds specifically suppressed HCV replication and may have potential as novel chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203602      PMCID: PMC3294916          DOI: 10.1128/AAC.05764-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

Review 3.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

4.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

5.  Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.

Authors:  N G Almstead; R S Bradley; S Pikul; B De; M G Natchus; Y O Taiwo; F Gu; L E Williams; B A Hynd; M J Janusz; C M Dunaway; G E Mieling
Journal:  J Med Chem       Date:  1999-11-04       Impact factor: 7.446

6.  Regulation of hepatitis C virus replication by interferon regulatory factor 1.

Authors:  Nobuhiko Kanazawa; Masayuki Kurosaki; Naoya Sakamoto; Nobuyuki Enomoto; Yasuhiro Itsui; Tsuyoshi Yamashiro; Yoko Tanabe; Shinya Maekawa; Mina Nakagawa; Cheng-Hsin Chen; Sei Kakinuma; Shigeru Oshima; Tetsuya Nakamura; Takanobu Kato; Takaji Wakita; Mamoru Watanabe
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Specific inhibition of hepatitis C virus replication by cyclosporin A.

Authors:  Mina Nakagawa; Naoya Sakamoto; Nobuyuki Enomoto; Yoko Tanabe; Nobuhiko Kanazawa; Tomoyuki Koyama; Masayuki Kurosaki; Shinya Maekawa; Tsuyoshi Yamashiro; Cheng Hsin Chen; Yasuhiro Itsui; Sei Kakinuma; Mamoru Watanabe
Journal:  Biochem Biophys Res Commun       Date:  2004-01-02       Impact factor: 3.575

8.  Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs.

Authors:  Takanori Yokota; Naoya Sakamoto; Nobuyuki Enomoto; Yoko Tanabe; Makoto Miyagishi; Shinya Maekawa; Li Yi; Masayuki Kurosaki; Kazunari Taira; Mamoru Watanabe; Hidehiro Mizusawa
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

9.  Agar sublimation test for the in vitro determination of the antifungal activity of morpholine derivatives.

Authors:  A Polak; A Jäckel; A Noack; R Kappe
Journal:  Mycoses       Date:  2004-06       Impact factor: 4.377

10.  Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.

Authors:  Yoko Tanabe; Naoya Sakamoto; Nobuyuki Enomoto; Masayuki Kurosaki; Eri Ueda; Shinya Maekawa; Tsuyoshi Yamashiro; Mina Nakagawa; Cheng-Hsin Chen; Nobuhiko Kanazawa; Sei Kakinuma; Mamoru Watanabe
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

View more
  3 in total

1.  CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses.

Authors:  Makoto Yamamoto; Hiroshi Onogi; Isao Kii; Suguru Yoshida; Kei Iida; Hiroyuki Sakai; Minako Abe; Toshiaki Tsubota; Nobutoshi Ito; Takamitsu Hosoya; Masatoshi Hagiwara
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

2.  Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus.

Authors:  Hui Shen; Atsuya Yamashita; Masamichi Nakakoshi; Hiromasa Yokoe; Masashi Sudo; Hirotake Kasai; Tomohisa Tanaka; Yuusuke Fujimoto; Masanori Ikeda; Nobuyuki Kato; Naoya Sakamoto; Hiroko Shindo; Shinya Maekawa; Nobuyuki Enomoto; Masayoshi Tsubuki; Kohji Moriishi
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

3.  An aromatic imidazoline derived from chloroquinoline triggers cell cycle arrest and inhibits with high selectivity the Trypanosoma cruzi mammalian host-cells infection.

Authors:  Roberto I Cuevas-Hernández; Richard M B M Girard; Luka Krstulović; Miroslav Bajić; Ariel Mariano Silber
Journal:  PLoS Negl Trop Dis       Date:  2021-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.